[广泛期小细胞肺癌的免疫治疗：研究进展与未来展望]
[Immunotherapy for Extensive-stage Small Cell Lung Cancer: Research Progress and Future Perspectives].
作者信息
Zhong Yuling, Wang Jingyi, Wu Lin
机构信息
Graduate Collaborative Training Base of Hunan Cancer Hospital, University of South China, Hengyang Medical School, Hengyang 421001, China.
The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):855-863. doi: 10.3779/j.issn.1009-3419.2024.102.35.
Abstract
At present, immunotherapy combined with chemotherapy has become the first-line standard of treatment for extensive-stage small cell lung cancer (ES-SCLC). In recent years, immune checkpoint inhibitors (ICIs) have received extensive attention and research in the field of lung cancer. At the same time, there are many challenges and tests in this process, such as the exploration of biomarkers, the exploration of new targets and new models, and the management of special populations. This article reviews the research progress in the field of ES-SCLC immunotherapy, and looks forward to the future development trend and potential direction of this field. .
摘要
目前，免疫疗法联合化疗已成为广泛期小细胞肺癌（ES-SCLC）的一线标准治疗方案。近年来，免疫检查点抑制剂（ICIs）在肺癌领域受到了广泛关注和研究。同时，这一过程中存在诸多挑战和考验，如生物标志物的探索、新靶点和新模型的探索以及特殊人群的管理等。本文综述了ES-SCLC免疫治疗领域的研究进展，并展望了该领域未来的发展趋势和潜在方向。
相似文献
1
[Immunotherapy for Extensive-stage Small Cell Lung Cancer:
Research Progress and Future Perspectives].[广泛期小细胞肺癌的免疫治疗：研究进展与未来展望]
Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):855-863. doi: 10.3779/j.issn.1009-3419.2024.102.35.
2
Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives.局限期小细胞肺癌的免疫治疗：创新疗法与未来展望
Cancer Control. 2025 Jan-Dec;32:10732748251334434. doi: 10.1177/10732748251334434. Epub 2025 Apr 14.
3
Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.构建中国最北部广泛期小细胞肺癌患者接受免疫治疗的预后模型，并基于不同时间点的反应状态预测治疗效果。
J Cancer Res Clin Oncol. 2024 May 15;150(5):255. doi: 10.1007/s00432-024-05767-6.
4
[Expert consensus on immunotherapy for small cell lung cancer (2025 edition)].[小细胞肺癌免疫治疗专家共识（2025年版）]
Zhonghua Zhong Liu Za Zhi. 2025 Jan 23;47(1):65-75. doi: 10.3760/cma.j.cn112152-20240905-00383. Epub 2024 Dec 5.
5
Deep analysis of the trials and major challenges in the first-line treatment for patients with extensive-stage small cell lung cancer.广泛期小细胞肺癌患者一线治疗的试验及主要挑战的深入分析
Int Immunopharmacol. 2025 Feb 20;148:114116. doi: 10.1016/j.intimp.2025.114116. Epub 2025 Jan 22.
6
Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study.广泛期小细胞肺癌一线化疗联合免疫治疗的疗效分析及预后因素：一项真实世界研究
Sci Rep. 2025 Apr 16;15(1):13063. doi: 10.1038/s41598-025-98018-8.
7
Recent advances in immunotherapy for small cell lung cancer.小细胞肺癌免疫治疗的最新进展
Curr Opin Oncol. 2025 Jan 1;37(1):17-26. doi: 10.1097/CCO.0000000000001105. Epub 2024 Nov 2.
8
[Advances in thoracic consolidation radiotherapy after first-line immunotherapy combined with chemotherapy for extensive stage small cell lung cancer].一线免疫治疗联合化疗后广泛期小细胞肺癌胸部巩固放疗的进展
Zhonghua Zhong Liu Za Zhi. 2024 Jun 23;46(6):526-535. doi: 10.3760/cma.j.cn112152-20230828-00102.
9
Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis.化疗联合免疫疗法作为广泛期老年小细胞肺癌患者的一线联合治疗方案：一项系统评价与荟萃分析。
Semin Oncol. 2025 Feb;52(1):14-18. doi: 10.1053/j.seminoncol.2024.11.001. Epub 2024 Dec 31.
10
Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.小细胞肺癌低剂量放疗联合免疫治疗的临床前研究和 II 期临床试验。
Med. 2024 Oct 11;5(10):1237-1254.e9. doi: 10.1016/j.medj.2024.06.002. Epub 2024 Jul 3.
本文引用的文献
1
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.广泛期小细胞肺癌一线抗程序性死亡配体1（PD-L1）治疗后的近期治疗模式及真实世界生存情况
Oncologist. 2024 Dec 6;29(12):1079-1089. doi: 10.1093/oncolo/oyae234.
2
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial.苏拉非尼联合特瑞普利单抗联合依托泊苷和顺铂作为晚期小细胞肺癌患者的一线治疗：一项 Ib/II 期试验。
Signal Transduct Target Ther. 2024 Sep 27;9(1):255. doi: 10.1038/s41392-024-01974-2.
3
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.本美司他滨、安罗替尼联合化疗治疗广泛期小细胞肺癌的随机 3 期临床试验。
Nat Med. 2024 Oct;30(10):2967-2976. doi: 10.1038/s41591-024-03132-1. Epub 2024 Jul 11.
4
Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.小细胞肺癌低剂量放疗联合免疫治疗的临床前研究和 II 期临床试验。
Med. 2024 Oct 11;5(10):1237-1254.e9. doi: 10.1016/j.medj.2024.06.002. Epub 2024 Jul 3.
5
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.替雷利珠单抗联合铂类和依托泊苷对比安慰剂联合铂类和依托泊苷一线治疗广泛期小细胞肺癌（RATIONALE-312）：一项多中心、双盲、安慰剂对照、随机、III 期临床研究。
J Thorac Oncol. 2024 Jul;19(7):1073-1085. doi: 10.1016/j.jtho.2024.03.008. Epub 2024 Mar 7.
6
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
7
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.特泊替尼治疗既往治疗的小细胞肺癌患者。
N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20.
8
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.塔拉拉单抗，一种首创的 DLL3 靶向双特异性 T 细胞衔接器，用于复发性小细胞肺癌：一项开放标签、I 期研究。
J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23.
9
Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.联合 PD-1 或 PD-L1 抑制剂与化疗治疗广泛期小细胞肺癌的疗效较好：一项临床研究的回顾性分析。
Front Immunol. 2022 Dec 5;13:1059557. doi: 10.3389/fimmu.2022.1059557. eCollection 2022.
10
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China.阿替利珠单抗联合依托泊苷/铂类治疗广泛期小细胞肺癌的临床结局：一项中国的真实世界、多中心、回顾性对照研究。
Chin J Cancer Res. 2022 Aug 30;34(4):353-364. doi: 10.21147/j.issn.1000-9604.2022.04.04.
Zotero 插件